Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Novavax JN.1 COVID-19 Vaccine (NVX-CoV2705)
NCT06409663Phase 3Completed
- Sponsor
- Novavax
- Start
- Oct 2024
- Primary completion
- Oct 2024
- Modality
- Recombinant Proteins and Enzymes, Nanoparticles, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of NVX-CoV2373 in coronavirus disease 2019 (COVID-19), sponsored by Novavax. Primary endpoints: Incidence, duration, and severity of solicited local and systemic adverse events at Day 7, Incidence, severity, and relationship of any unsolicited adverse events at Day 28 and 1 more. Started Oct 2024; status: completed.
02
Drugs
NVX-CoV2373
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT06409663.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06409663.